Co-Diagnostics, Inc. Common Stock

Co-Diagnostics, Inc. and ReadyGo Diagnostics Ltd. announced a collaboration to evaluate the potential use of ReadyGo's sample-preparation technology with the Co-Dx PCR platform for blood-based molecular testing at the point of need, with an initial focus on decentralized Ebola virus detection and outbreak response. The companies are evaluating two potentially complementary technologies: the Co-Dx PCR platform, a point-of-need PCR technology, and GoCollect by ReadyGo, a field sample-preparation system that prepares blood samples for molecular testing at the point of need. The collaboration builds on Co-Dx's earlier proof-of-concept work testing an Ebola assay using plasma as a sample type, and establishing blood as a compatible sample type would extend the Co-Dx PCR platform beyond the swab-based testing it supports today into bloodborne pathogens such as HIV and hepatitis B and C. The companies have begun feasibility work and Co-Dx has taken delivery of ReadyGo materials and devices to support that evaluation, though there can be no assurance that the evaluation will be successful or result in a commercially available product. In the ongoing outbreak in the Democratic Republic of the Congo, the World Health Organization has reported 6,757 confirmed cases and 3,267 deaths as of Sept 7, 2026, for a case fatality rate of approximately 48%, with 61 health zones affected across six provinces, and the WHO has described this as the second-largest Ebola outbreak on record. Co-Dx will host a live press conference and webcast on Wednesday, September 16, 2026, at 10:30 a.m. ET to discuss the collaboration.